These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15026542)

  • 1. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
    July LV; Beraldi E; So A; Fazli L; Evans K; English JC; Gleave ME
    Mol Cancer Ther; 2004 Mar; 3(3):223-32. PubMed ID: 15026542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
    So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
    Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro.
    Chung J; Kwak C; Jin RJ; Lee CH; Lee KH; Lee SE
    Cancer Lett; 2004 Jan; 203(2):155-61. PubMed ID: 14732223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
    Zhao XY; Nie CL; Liang SF; Yuan Z; Deng HX; Wei YQ
    Biomed Pharmacother; 2012 Dec; 66(8):597-602. PubMed ID: 23153503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
    Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
    Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM; Jackson JK; Gleave ME; Burt HM
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
    Zhang B; Liu ZM; Hao FG; Wang M
    Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.
    Miyake H; Eto H; Hara I; So A; Li D; Gleave ME
    J Urol; 2004 Jun; 171(6 Pt 1):2477-81. PubMed ID: 15126879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
    Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M; Miyake H
    World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells.
    Cao YD; Huang PL; Sun XC; Ma J; Jin ZL; Cheng HY; Xu RZ; Li F; Qin SK; Deng YX; Ge XL
    Chin Med J (Engl); 2011 Apr; 124(7):1061-8. PubMed ID: 21542969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clusterin confers gemcitabine resistance in pancreatic cancer.
    Chen Q; Wang Z; Zhang K; Liu X; Cao W; Zhang L; Zhang S; Yan B; Wang Y; Xia C
    World J Surg Oncol; 2011 May; 9():59. PubMed ID: 21609464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L; Bali P; Wittmann S; Donapaty S; Guo F; Yamaguchi H; Wang HG; Atadja P; Bhalla K
    Mol Cancer Ther; 2003 Oct; 2(10):971-84. PubMed ID: 14578462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.